Pfizer Inc. is threatening legal action at an attempt by Novo Nordisk A/S to scupper its acquisition of Metsera Inc., with an unsolicited $9 billion offer for the anti-obesity specialist. That trumps ...
Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...
Novo Nordisk has made an unsolicited, approximately up to $9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion.
Pedersen, Louise Rasmussen and Maggie Fick COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity ...
Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...
Roblox posted a wider third-quarter loss but boosted its revenue forecast for the year as a pair of videogaming crazes generated robust top-line growth. Fox logged higher revenue in its fiscal first ...
Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...
The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were ...
US President Trump wraps up his Asia tour with major trade and security announcements, while Israel’s Netanyahu issues a ...
Pfizer may sue Novo Nordisk and Metsera over a $9B takeover bid, alleging antitrust risks and regulatory evasion.
The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Lilly and spawning a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback